1800-272-662
Shopping Cart 0
countryflagAU
Login

Opthea Ltd

Healthcare AU OPT

0.6AUD
-(-%)

Last update at 2026-03-11T23:00:00Z

Day Range

0.600.60
LowHigh

52 Week Range

0.600.60
LowHigh

Fundamentals

  • Previous Close 0.60
  • Market Cap820.79M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-109.39400M
  • Revenue TTM-0.02012M
  • Revenue Per Share TTM-
  • Gross Profit TTM -0.02012M
  • Diluted EPS TTM-0.43

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -169.73800M -229.65430M -148.44744M -99.11666M -50.28334M
Minority interest - - - - -
Net income -162.79100M -220.24211M -142.52108M -92.81737M -45.34450M
Selling general administrative 20.54M 15.49M 27.84M 17.83M 13.72M
Selling and marketing expenses - - - - -
Gross profit 0.03M 0.12M 0.11M 0.09M 0.07M
Reconciled depreciation 0.09M 0.10M 0.10M 0.08M 0.11M
Ebit -123.28100M -199.39126M -146.79830M -93.72380M -28.62855M
Ebitda -123.19000M -199.28823M -146.69707M -93.64542M -28.52189M
Depreciation and amortization 0.09M 0.10M 0.10M 0.08M 0.11M
Non operating income net other - - - - -
Operating income -155.76200M -191.84273M -146.79830M -93.72380M -28.62855M
Other operating expenses 155.79M 191.97M 150.13M 96.63M 39.71M
Interest expense 46.46M 30.26M 13.46M 0.24M 21.65M
Tax provision -6.94700M -9.41220M -5.92635M -6.29929M -4.93885M
Interest income 5.53M 3.39M 1.58M 0.24M 0.37M
Net interest income -40.92500M -26.86832M -10.23466M 0.24M 0.37M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -6.94700M -9.41220M -5.92635M -6.29929M -4.93885M
Total revenue 0.03M 0.12M 0.11M 0.09M 0.07M
Total operating expenses 155.79M 191.97M 150.13M 96.63M 39.71M
Cost of revenue - - 0.17M 0.16M 0.43M
Total other income expense net -13.97600M -37.81157M 11.81M -5.39286M -21.65479M
Discontinued operations - - - - -
Net income from continuing ops -162.79100M -220.24211M -142.52108M -92.81737M -45.34450M
Net income applicable to common shares -162.79100M -220.24211M -142.52109M -92.81737M -45.34450M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 56.80M 188.79M 98.64M 60.05M 138.41M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets - - - 8.72M 14.39M
Total liab 257.87M 264.60M 104.40M 12.07M 3.12M
Total stockholder equity -201.06900M -75.81008M -5.75855M 47.98M 135.29M
Deferred long term liab - - - - -
Other current liab 246.99M 24.84M 0.75M 0.64M 0.58M
Common stock - 466.08M 320.88M 235.28M 234.15M
Capital stock 497.49M 466.08M 320.88M 235.28M 234.15M
Retained earnings -742.49500M -579.70454M -359.36781M -216.94135M -124.12398M
Other liab - - 0.00763M 0.03M 0.02M
Good will - - - - -
Other assets - - 0.05M 0.11M 0.17M
Cash 48.44M 172.47M 89.19M 44.63M 118.19M
Cash and equivalents - - 77.12M 32.78M 102.65M
Total current liabilities 257.87M 64.06M 18.65M 12.04M 3.11M
Current deferred revenue - 1.06M - - -
Net debt - -30.82366M -89.00700M -44.63129M -118.08021M
Short term debt - 0.09M 0.10M 0.00000M 0.11M
Short long term debt - - - - -
Short long term debt total - 141.65M 0.18M - 0.11M
Other stockholder equity - - 20.09M 29.64M 25.26M
Property plant equipment - - 0.20M 0.03M 0.12M
Total current assets 56.80M 188.19M 98.39M 59.91M 138.12M
Long term investments - - - - 0.00000M
Net tangible assets - - -5.85318M 47.98M 135.29M
Short term investments - - - - -
Net receivables - 11.82M 6.56M 6.56M 5.54M
Long term debt - 141.55M 85.66M - -
Inventory - - - - -
Accounts payable 9.74M 38.06M 17.80M 11.40M 2.42M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - 37.81M 32.73M 29.64M 25.26M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.47M 0.05M 0.11M 0.17M
Deferred long term asset charges - - - - -
Non current assets total 0.00000M 0.60M 0.26M 0.14M 0.29M
Capital lease obligations 0.00000M 0.09M 0.18M 0.00000M 0.11M
Long term debt total - - 85.74M 0.00000M 0.00000M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.01300M -0.03349M -0.02195M -0.01691M 0.67M
Change to liabilities - - 7.30M 8.51M -1.55244M
Total cashflows from investing activities -0.01300M -0.03349M -0.02195M -0.01691M 0.66M
Net borrowings -0.09300M -0.08900M 84.43M -0.08558M -0.08737M
Total cash from financing activities 34.77M 243.73M 248.70M 0.24M 156.76M
Change to operating activities - - 6.28M 5.85M -14.19104M
Net income -162.79100M -220.24211M -211.88068M -127.99021M -60.78802M
Change in cash -124.02800M 83.28M 69.08M -92.52939M 95.41M
Begin period cash flow 172.47M 89.19M 64.90M 157.43M 62.02M
End period cash flow 48.44M 172.47M 133.99M 64.90M 157.43M
Total cash from operating activities -158.64400M -161.01535M -179.30389M -98.36710M -61.05838M
Issuance of capital stock 34.81M 158.82M 81.82M 0.00000M 105.48M
Depreciation - 0.10M 0.15M 0.11M 0.14M
Other cashflows from investing activities - - - 0.00000M 0.67M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - -0.78984M 0.56M 0.42M -0.49563M
Sale purchase of stock 34.86M 243.82M 167.36M 0.26M 117.02M
Other cashflows from financing activities 0.05M 85.00M -0.03454M -0.03243M -0.02976M
Change to netincome - - 7.86M 6.74M 15.80M
Capital expenditures 0.01M 0.03M 0.03M 0.02M 0.02M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 5.92M 17.30M 20.75M 20.22M -21.60105M
Stock based compensation - 5.08M 5.83M 5.25M 3.90M
Other non cash items -158.64400M 46.15M 11.77M 10.34M 22.23M
Free cash flow -158.65700M -161.04884M -179.33653M -98.39042M -61.07541M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
OPT
Opthea Ltd		 - -% 0.60 - 6.75 5621.83 4.21 466.68 -1.0623
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Opthea Limited, a clinical-stage biopharmaceutical company, researches and develops therapeutic products based on targeting vascular endothelial growth factors (VEGF) C, D and R3 in Australia and the United States. The company's pipeline includes Sozinibercept, which is in phase 3 to treat wet age-related macular degeneration (Wet AMD), as well as in phase 2 to treat diabetic macular edema (DME). It serves the biotechnology and healthcare industries. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is headquartered in Melbourne, Australia.

Opthea Ltd

Level 9, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. MD, CEO & Exec. Director 1974
Ms. Judith J. Robertson B.A., M.B.A. Chief Commercial Officer 1960
Dr. Joel Naor M.D., MBA, MSc Chief Medical Officer NA
Ms. Karen Adams CPA VP of Fin. & Company Sec. 1971
Mr. Timothy E. Morris CPA, CPA Chief Financial Officer 1961
Ms. Annie Lee Fin. & Operations Mang. NA
Dr. Michael Gerometta Ph.D. Head of Chemistry, Manufacturing & Controls Devel. 1964
Mr. Bruno Gagnon BPHARM, M.Sc. Sr. VP of Global Clinical Operations NA
Dr. Ian Leitch Director of Clinical Research 1963
Dr. James Goding Independent Consultant NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.